AUTHOR=Drieux Fanny , Lemonnier François , Gaulard Philippe 

TITLE=How molecular advances may improve the diagnosis and management of PTCL patients

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1202964

DOI=10.3389/fonc.2023.1202964

ISSN=2234-943X

ABSTRACT=Peripheral T-cell lymphomas (PTCL) represent 10 to 15% of adult non-Hodgkin lymphomas. In the
latest revised WHO and ICC classifications (1,2), more than 30 entities are described, mostly defined
by their clinical and pathological and phenotypic features, with a growing element of molecular data.
Indeed, molecular studies based on high-throughput technologies have allowed for a better
understanding of the oncogenic mechanisms involved and have improved the characterization of
several entities. Although only a few specific genomic alterations define a given entity, the use of
molecular data, such as clonality assays and targeted next-generation sequencing (NGS), is now
integrated into the routine diagnostic workflow of expert centers, in combination with clinical and
pathological clues. However, the translation of high-throughput genomic studies to clinical practice is
still limited due to the high cost of high-throughput technologies and little clinical relevance for most
findings. In this review, we will detail the oncogenic mechanisms of the main non-cutaneous PTCL
entities, the molecular targets that have an impact on their diagnosis or treatment, and the assays
that are useful for the detection of these clinically relevant molecular alterations(3). Entities with a
leukemic presentation (notably T-cell large granular lymphocytic leukemia and T-prolymphocytic
leukemia) will not be detailed.